We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mallinckrodt Plc () | USOTC:MNKKQ | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.02 | 0.00 | 01:00:00 |
By Colin Kellaher
ANI Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration has accepted its application to reintroduce its Cortrophin Gel treatment for patients with chronic auto-immune disorders.
The Baudette, Minn., pharmaceutical company said the agency set a target action date of Oct. 29 for the potential competitor to Mallinckrodt PLC's Acthar Gel.
The FDA originally approved Cortrophin Gel in 1954, but it was last used in patients in the 1980s. The product has more than 54 indications on its previously approved label, including the treatment of acute exacerbations of multiple sclerosis, rheumatoid arthritis and nephrotic syndrome.
ANI, which acquired Cortrophin Gel from Merck in early 2016 and spent more than $100 million to re-establish the product, last year filed for FDA approval to reintroduce it to the U.S. market.
However, the agency turned the application away, citing concerns related to chemistry, manufacturing and controls section. ANI resubmitted the application in June.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 31, 2021 08:53 ET (12:53 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Mallinckrodt () Chart |
1 Month Mallinckrodt () Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions